" class="no-js "lang="en-US"> HemoShear Develops New Human Tissue-Based Model of Rare Liver Disease Under Research Collaboration with Takeda - Medtech Alert
Tuesday, April 23, 2024

HemoShear Develops New Human Tissue-Based Model of Rare Liver Disease Under Research Collaboration with Takeda

HemoShear Therapeutics, Inc., a privately held clinical stage biotechnology company, has received a milestone payment under its October 2020 research collaboration and service agreement with Takeda. The milestone acknowledges development of a human tissue-based model of an undisclosed rare liver disease using the company’s REVEAL-Tx platform. REVEAL-Tx™ combines physiological and computational models of disease to identify novel treatment approaches and select drug candidates in a human-relevant disease context.

In 2021, HemoShear completed a four-year collaboration with Takeda resulting in two novel drug targets for nonalcoholic steatohepatitis (NASH) advancing into Takeda’s Discovery Portfolio.

“I am incredibly proud of our team who went to exhaustive efforts to develop and validate a new rare liver disease model,” said M. Sol Collado, PhD, head of discovery biology. “With this model now available to Takeda and HemoShear scientists, we are initiating an accelerated research plan to assess therapeutic approaches and monitor impact on biomarkers.”

“HemoShear has continued to deliver throughout our liver disease research partnerships,” said Bernard Allan, PhD, head of liver research and drug discovery at Takeda. “We look forward to building on our momentum utilizing HemoShear’s platform and scientific team to help evaluate potential new treatments for a challenging rare liver disease with high unmet need.”

People In This Post

Companies In This Post

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more